HIMS Q3 Earnings Preview: After Setback in Weight Loss Drugs, Hims Stands at a Crossroads

Hims' core positioning is as a platform business connecting patients with personalized medical solutions. Its true value lies not in new drug development, but in its ability to design, personalize, and streamline the healthcare experience. By integrating technology, medical services, and user engagement, it transforms the traditionally fragmented medical process into a smooth, empowering experience for millions of users.

However, the company faced several challenges in Q2: negative cash flow, revenue below expectations, declining GLP-1 business, slowing user growth, and the termination of its partnership with Novo Nordisk. More critically, Trump's proposal to drastically reduce the pricing of popular weight loss drugs from $1,300 to $150 could directly impact the market share of Hims' similarly priced compound GLP-1 drugs if implemented. Under these multiple pressures, the company's stock price has fallen by over 30% since the last earnings report.

To address these challenges, Hims has initiated several strategic adjustments. In the weight loss business, the company plans to focus on promoting non-injectable solutions in the second half of 2025, including compound oral medications such as bupropion/naltrexone and metformin/sitagliptin. These products offer improved tolerability through optimized formulations and provide differentiated options for various BMI groups. Additionally, Hims will launch a generic version of the liraglutide injection. As another GLP-1 drug from Novo Nordisk with an expiring patent, it's expected to be priced at $200-300 per month, significantly lower than the original drug, aiming to fill the market gap left by Wegovy's withdrawal.

In core businesses, traditional segments such as hair loss treatment, sexual health, and dermatology remain resilient. Data shows that about 70% of subscription users opt for comprehensive treatment plans covering weight loss, hair loss, sexual health, and mental health, reflecting synergies across its businesses. Furthermore, the company is actively exploring new growth areas, including hormone health, laboratory testing, and longevity. In June, Hims announced the acquisition of European telemedicine company ZAVA, successfully entering European markets including the UK, Germany, Ireland, and France, demonstrating its strategic intent to alleviate growth pressure in core markets through regional expansion.

1. Legal and Regulatory Adaptability: Can Hims continue to develop its compound drugs and personalized treatment solutions compliantly in the context of stricter FDA reviews and increasing influence of large pharmaceutical companies?

2. Sustainability and New Momentum in Core Businesses: Can traditional segments like hair loss and sexual health maintain growth resilience? In an environment where GLP-1 business faces pressure, can the company significantly increase user scale with non-GLP-1 products?

3. Expansion Efficiency in New Vertical Areas: Can management accelerate the layout and scaling in new areas such as diagnostics, chronic disease management, and fertility? The platform's scalability will be key to capturing larger market opportunities.

4. Healthy Transition of Growth Model: Can Hims gradually reduce its dependence on paid marketing and shift towards sustainable growth through brand assets, organic channels, and user retention? This will be a core indicator distinguishing efficient platforms from stagnant enterprises.

Options on Hims are setting up for an active earnings print after the Nov. 3 close. Total open interest sits around 1.15 million contracts, with a put/call ratio near 1.1, signaling slightly more hedging than outright bullish speculation. Implied volatility is elevated at roughly 103% and broadly in line with realized vol (~100%), but the IV rank is only in the high 30s and IV percentile near 50%, suggesting the market is pricing a meaningful move without panic-level premiums.

Overall, positioning looks balanced-to-cautious ahead of results, with traders paying up for protection rather than chasing a one-sided upside bet.

Summary

This earnings report is Hims to test of the resilience of its core platform model. The market's focus has shifted from the "weight loss drug story" itself to a more fundamental question: In the face of external shocks, can Hims' platform capability to integrate technology, healthcare, and services continue to drive high-quality growth?

These factors will be crucial in determining whether Hims can successfully navigate its current challenges and emerge as a stronger, more diversified healthcare platform.